Portal de Periódicos da CAPES

German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids)

2012; Wiley; Volume: 10; Issue: 10 Linguagem: Inglês

10.1111/j.1610-0387.2012.08012.x

1610-0387

Alexander Nast, Sabine A. Eming, Joachim W. Fluhr, Klaus Fritz, Gerd G. Gauglitz, Silvia Hohenleutner, Renato G. Panizzon, Günther Sebastian, Birte Sporbeck, Josef Koller,

Genetic and rare skin diseases.

JDDG: Journal der Deutschen Dermatologischen GesellschaftVolume 10, Issue 10 p. 747-760 Guideline German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids) Alexander Nast, Alexander Nast Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Charité– Universitätsmedizin Berlin, GermanySearch for more papers by this authorSabine Eming, Sabine Eming Department of Dermatology and Venereology, University of Cologne, GermanySearch for more papers by this authorJoachim Fluhr, Joachim Fluhr Department of Dermatology, Charité– Universitätsmedizin Berlin, GermanySearch for more papers by this authorKlaus Fritz, Klaus Fritz Dermatologists and Laser Center Landau and Kandel, Landau (Lower Palatinate)/Kandel, Germany; Department of Dermatology, Inselspital Bern, Switzerland; Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, GermanySearch for more papers by this authorGerd Gauglitz, Gerd Gauglitz Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, GermanySearch for more papers by this authorSilvia Hohenleutner, Silvia Hohenleutner Department of Dermatology, University of Regensburg, GermanySearch for more papers by this authorRenato G. Panizzon, Renato G. Panizzon University Clinic for Dermatology, Lausanne, SwitzerlandSearch for more papers by this authorGünther Sebastian, Günther Sebastian Dermatologist, Dresden, GermanySearch for more papers by this authorBirte Sporbeck, Birte Sporbeck Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Charité– Universitätsmedizin Berlin, GermanySearch for more papers by this authorJosef Koller, Josef Koller University Clinic for Dermatology, Salzburg State Hospital, University Clinic of the PMU, Salzburg, AustriaSearch for more papers by this author Alexander Nast, Alexander Nast Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Charité– Universitätsmedizin Berlin, GermanySearch for more papers by this authorSabine Eming, Sabine Eming Department of Dermatology and Venereology, University of Cologne, GermanySearch for more papers by this authorJoachim Fluhr, Joachim Fluhr Department of Dermatology, Charité– Universitätsmedizin Berlin, GermanySearch for more papers by this authorKlaus Fritz, Klaus Fritz Dermatologists and Laser Center Landau and Kandel, Landau (Lower Palatinate)/Kandel, Germany; Department of Dermatology, Inselspital Bern, Switzerland; Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, GermanySearch for more papers by this authorGerd Gauglitz, Gerd Gauglitz Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, GermanySearch for more papers by this authorSilvia Hohenleutner, Silvia Hohenleutner Department of Dermatology, University of Regensburg, GermanySearch for more papers by this authorRenato G. Panizzon, Renato G. Panizzon University Clinic for Dermatology, Lausanne, SwitzerlandSearch for more papers by this authorGünther Sebastian, Günther Sebastian Dermatologist, Dresden, GermanySearch for more papers by this authorBirte Sporbeck, Birte Sporbeck Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Charité– Universitätsmedizin Berlin, GermanySearch for more papers by this authorJosef Koller, Josef Koller University Clinic for Dermatology, Salzburg State Hospital, University Clinic of the PMU, Salzburg, AustriaSearch for more papers by this author First published: 03 September 2012 https://doi.org/10.1111/j.1610-0387.2012.08012.xCitations: 28 PD Dr. Alexander Nast, Department of Dermatology, Venereology and Allergology, Charité– Universitätsmedizin Berlin, Charité Campus Mitte, Charitéplatz 1, D-10117 Berlin, Germany. Tel.: +49-30-450-518-313 Fax: +49-30-450-518-977 E-mail: [email protected] Section Editor PD Dr. Alexander Nast, Berlin Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Koller J, Sebastian G. Therapie pathologischer Narben (hypertrophe Narben und Keloide). J Dtsch Dermatol Ges 2004; 2: 308–12. 2 Leitlinien-Manual von AWMF und ÄZQ. Z ärztl Fortbild Qualsich (ZaeFQ) 2001; 95. 3 Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008; 453: 314–21. 4 Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349–63. 5 Larson BJ, Longaker MT, Lorenz HP. Scarless fetal wound healing: a basic science review. Plast Reconstr Surg 2010; 126: 1172–80. 6 Marneros AG, Krieg T. Keloids-clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges 2004; 2: 905–13. 7 Eckes B, Nischt R, Krieg T. Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair 2010; 3: 4. 8 Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007; 179: 1311–23. 9 Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H, Occleston NL, Sattar A, Ludlow A, O'Kane S. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009; 373: 1264–74. 10 Shih B, Bayat A. Comparative genomic hybridisation analysis of keloid tissue in Caucasians suggests possible involvement of HLA-DRB5 in disease pathogenesis. Arch Dermatol Res 2011. 11 Shih B, Bayat A. Genetics of keloid scarring. Arch Dermatol Res 2010; 302: 319–39. 12 Balci DD, Inandi T, Dogramaci CA, Celik E. DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study. J Dtsch Dermatol Ges 2009; 7: 688–92. 13 Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297: 433–8. 14 Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring devices. Eplasty 2010; 10: e43. 15 Perry DM, McGrouther DA, Bayat A. Current tools for noninvasive objective assessment of skin scars. Plast Reconstr Surg 2010; 126: 912–23. 16 Sebastian G, Hackert I, Stein A, Aschoff R. Möglichkeiten zur Objektivierung der Effizienz der Kryotherapie bei Keloiden. In: J Koller, H Hutner: Fortschritte der operativen und onkologischen Dermatologie. Berlin , Wien : Blackwell, 2000: 192–7. 17 Schaffer MR, Efron PA, Thornton FJ, Klingel K, Gross SS, Barbul A. Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol 1997; 158: 2375–81. 18 Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007; 25: 26–32. 19 Anthony ET, Lemonas P, Navsaria HA, Moir GC. The cost effectiveness of intralesional steroid therapy for keloids. Dermatol Surg 2010; 36: 1624–6. 20 Ceilley RI, Babin RW. The combined use of cryosurgery and intralesional injections of suspensions of fluorinated adrenocorticosteroids for reducing keloids and hypertrophic scars. J Dermatol Surg Oncol 1979; 5: 54–6. 21 Tang YW. Intra- and postoperative steroid injections for keloids and hypertrophic scars. Br J Plast Surg 1992; 45: 371–3. 22 Zouboulis CC, Blume U, Buttner P, Orfanos CE. Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series. Arch Dermatol 1993; 129: 1146–51. 23 Ernst K, Hundeiker M. [Results of cryosurgery in 394 patients with hypertrophic scars and keloids]. Hautarzt 1995; 46: 462–6. 24 Anzarut A, Olson J, Singh P, Rowe BH, Tredget EE. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. J Plast Reconstr Aesthet Surg 2009; 62: 77–84. 25 Bran GM, Brom J, Hormann K, Stuck BA. Auricular Keloids: Combined Therapy With a New Pressure Device. Arch Facial Plast Surg 2011. 26 Kadouch DJ, van der Veer WM, Mahdavian Delavary B, Kerkdijk D, Niessen FB. Therapeutic hotline: An alternative adjuvant treatment after ear keloid excision using a custom-made methyl methacrylate stent. Dermatol Ther 2010; 23: 686–92. 27 Candy LH, Cecilia LT, Ping ZY. Effect of different pressure magnitudes on hypertrophic scar in a Chinese population. Burns 2010; 36: 1234–41. 28 Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg 2008; 61: 4–17. 29 Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, Stella M, Téot L, Wood FM, Ziegler UE. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560–71. 30 Tan KT, Shah N, Pritchard SA, McGrouther DA, Bayat A. The influence of surgical excision margins on keloid prognosis. Ann Plast Surg 2010; 64: 55–8. 31 Lee Y, Minn KW, Baek RM, Hong JJ. A new surgical treatment of keloid: keloid core excision. Ann Plast Surg 2001; 46: 135–40. 32 Kim DY, Kim ES, Eo SR, Kim KS, Lee SY, Cho BH. A surgical approach for earlobe keloid: keloid fillet flap. Plast Reconstr Surg 2004; 113: 1668–74. 33 Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 2010; 125: 557–68. 34 Music EN, Engel G. Earlobe keloids: a novel and elegant surgical approach. Dermatol Surg 2010; 36: 395–400. 35 Rosen DJ, Patel MK, Freeman K, Weiss PR. A primary protocol for the management of ear keloids: results of excision combined with intraoperative and postoperative steroid injections. Plast Reconstr Surg 2007; 120: 1395–400. 36 Park TH, Seo SW, Kim JK, Chang CH. Outcomes of surgical excision with pressure therapy using magnets and identification of risk factors for recurrent keloids. Plast Reconstr Surg 2011; 128: 431–9. 37 Hassel JC, Loser C, Koenen W, Kreuter A, Hassel AJ. Promising results from a pilot study on compression treatment of ear keloids. J Cutan Med Surg 2011; 15: 130–6. 38 Ragoowansi R, Cornes PG, Moss AL, Glees JP. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast Reconstr Surg 2003; 111: 1853–9. 39 van de Kar AL, Kreulen M, van Zuijlen PP, Oldenburger F. The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: a prospective clinical outcome study. Plast Reconstr Surg 2007; 119: 2248–54. 40 O'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2006: CD003826. 41 Cacao FM, Tanaka V, Messina MC. Failure of imiquimod 5 % cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg 2009; 35: 629–33. 42 Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5 % cream for the prevention of recurrence after excision of presternal keloids. Dermatology 2007; 215: 63–5. 43 Wolfram D, Tzankov A, Pulzl P, Piza-Katzer H. Hypertrophic scars and keloids – a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009; 35: 171–81. 44 Apfelberg DB, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9: 382–8. 45 Saivon Y, Mordechai S, Sharon-Buller A. Pressure Earring as an Adjunct to Surgical Removal of Earlobe Keloids. Dermatol Surg 2009; 35: 190–2. 46 Jung JY, Jeong JJ, Roh HJ, Cho SH, Chung KY, Lee WJ, Nam KH, Chung WY, Lee JH. Early postoperative treatment of thyroidectomy scars using a fractional carbon dioxide laser. Dermatol Surg 2011; 37: 217–23. 47 Waibel J, Beer K. Ablative fractional laser resurfacing for the treatment of a third-degree burn. J Drugs Dermatol 2009; 8: 294–7. 48 Wagner JA, Paasch U, Bodendorf MO, Simon JC, Grunewald S. Treatment of keloids and hypertrophic scars with the triple-mode Er:YAG laser: a pilot study. Med Laser Appl 2011; 26: 10–5. 49 Kuo YR, Wu WS, Jeng SF, Huang HC, Yang KD, Sacks JM, Wang FS. Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye laser treatment. Lasers Surg Med 2005; 36: 31–7. 50 Kuo YR, Wu WS, Jeng SF, Wang FS, Huang HC, Lin CZ, Yang KD. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg Med 2005; 36: 38–42. 51 Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345: 1198–200. 52 Paquet P, Hermanns JF, Pierard GE. Effect of the 585 nm flashlamp-pumped pulsed dye laser for the treatment of keloids. Dermatol Surg 2001; 27: 171–4. 53 Allison KP, Kiernan MN, Waters RA, Clement RM. Pulsed dye laser treatment of burn scars. Alleviation or irritation Burns 2003; 29: 207–13. 54 Wittenberg GP, Fabian BG, Bogomilsky JL, Schultz LR, Rudner EJ, Chaffins ML, Saed GM, Burns RL, Fivenson DP. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Arch Dermatol 1999; 135: 1049–55. 55 Elsaie ML, Choudhary S. Lasers for scars: a review and evidence-based appraisal. J Drugs Dermatol 2010; 9: 1355–62. 56 Alster T, Zaulyanov L. Laser scar revision: a review. Dermatol Surg 2007; 33: 131–40. 57 Haedersdal M, Moreau KE, Beyer DM, Nymann P, Alsbjorn B. Fractional nonablative 1540 nm laser resurfacing for thermal burn scars: a randomized controlled trial. Lasers Surg Med 2009; 41: 189–95. 58 Escarmant P, Zimmermann S, Amar A, Ratoanina JL, Moris A, Azaloux H, Francois H, Gosserez O, Michel M, G'Baguidi R. The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision. Int J Radiat Oncol Biol Phys 1993; 26: 245–51. 59 Guix B, Henriquez I, Andres A, Finestres F, Tello JI, Martinez A. Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol Biol Phys 2001; 50: 167–72. 60 Sallstrom KO, Larson O, Heden P, Eriksson G, Glas JE, Ringborg U. Treatment of keloids with surgical excision and postoperative X-ray radiation. Scand J Plast Reconstr Surg Hand Surg 1989; 23: 211–5. 61 Doornbos JF, Stoffel TJ, Hass AC, Hussey DH, Vigliotti AP, Wen BC, Zahra MK, Sundeen V. The role of kilovoltage irradiation in the treatment of keloids. Int J Radiat Oncol Biol Phys 1990; 18: 833–9. 62 Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg 2008; 32: 82–92. 63 Eishi K, Bae SJ, Ogawa F, Hamasaki Y, Shimizu K, Katayama I. Silicone gel sheets relieve pain and pruritus with clinical improvement of keloid: possible target of mast cells. J Dermatolog Treat 2003; 14: 248–52. 64 Cho JW, Cho SY, Lee SR, Lee KS. Onion extract and quercetin induce matrix metalloproteinase-1 in vitro and in vivo. Int J Mol Med 2010; 25: 347–52. 65 Phan TT, Lim IJ, Chan SY, Tan EK, Lee ST, Longaker MT. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma 2004; 57: 1032–7. 66 Maragakis M, Willital GH, Michel G, Gortelmeyer R. Possibilities of scar treatment after thoracic surgery. Drugs Exp Clin Res 1995; 21: 199–206. 67 Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg 2006; 32: 193–7. 68 Koc E, Arca E, Surucu B, Kurumlu Z. An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. Dermatol Surg 2008; 34: 1507–14. 69 Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004; 30: 54–6; discussion 56–7. 70 Liu W, Wu X, Gao Z, Song N. Remodelling of keloid tissue into normal-looking skin. J Plast Reconstr Aesthet Surg 2008; 61: 1553–4. 71 Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138: 1149–55. 72 Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, Crane A. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J 2009; 29: 40–6. 73 Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 2006; 32: 907–15. 74 Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2009; 34: 219–23. 75 Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology 2002; 204: 130–2. 76 Shridharani SM, Magarakis M, Manson PN, Singh NK, Basdag B, Rosson GD. The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review. Ann Plast Surg 2010; 64: 355–61. 77 Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol 2008; 47: 183–6. Citing Literature Volume10, Issue10October 2012Pages 747-760 ReferencesRelatedInformation